Annual CFF
$11.97 M
-$17.68 M-59.61%
September 30, 2024
Summary
- As of February 7, 2025, AVXL annual cash flow from financing activities is $11.97 million, with the most recent change of -$17.68 million (-59.61%) on September 30, 2024.
- During the last 3 years, AVXL annual CFF has fallen by -$141.27 million (-92.19%).
- AVXL annual CFF is now -92.19% below its all-time high of $153.24 million, reached on September 30, 2021.
Performance
AVXL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$89.00 K
-$4.46 M-98.04%
September 30, 2024
Summary
- As of February 7, 2025, AVXL quarterly cash flow from financing activities is $89.00 thousand, with the most recent change of -$4.46 million (-98.04%) on September 30, 2024.
- Over the past year, AVXL quarterly CFF has dropped by -$4.46 million (-98.04%).
- AVXL quarterly CFF is now -99.90% below its all-time high of $89.22 million, reached on June 30, 2021.
Performance
AVXL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$11.97 M
-$1.97 M-14.11%
September 30, 2024
Summary
- As of February 7, 2025, AVXL TTM cash flow from financing activities is $11.97 million, with the most recent change of -$1.97 million (-14.11%) on September 30, 2024.
- Over the past year, AVXL TTM CFF has dropped by -$1.97 million (-14.11%).
- AVXL TTM CFF is now -92.46% below its all-time high of $158.90 million, reached on June 30, 2021.
Performance
AVXL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AVXL Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -59.6% | -98.0% | -14.1% |
| 3 y3 years | -92.2% | -96.0% | -92.2% |
| 5 y5 years | -32.7% | -96.0% | -92.2% |
AVXL Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -92.2% | at low | -99.5% | +3460.0% | -90.8% | at low |
| 5 y | 5-year | -92.2% | at low | -99.9% | +3460.0% | -92.5% | at low |
| alltime | all time | -92.2% | >+9999.0% | -99.9% | +153.8% | -92.5% | -100.0% |
Anavex Life Sciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | $11.97 M(-59.6%) | $89.00 K(-98.0%) | $11.97 M(-14.1%) |
| Jun 2024 | - | $4.55 M(-37.5%) | $13.94 M(-24.2%) |
| Mar 2024 | - | $7.28 M(>+9900.0%) | $18.39 M(-37.5%) |
| Dec 2023 | - | $59.00 K(-97.1%) | $29.45 M(-0.7%) |
| Sep 2023 | $29.65 M(+39.3%) | $2.06 M(-77.2%) | $29.65 M(+7.4%) |
| Jun 2023 | - | $9.00 M(-50.9%) | $27.60 M(+8.2%) |
| Mar 2023 | - | $18.33 M(+7006.2%) | $25.50 M(+34.2%) |
| Dec 2022 | - | $258.00 K(>+9900.0%) | $19.01 M(-10.7%) |
| Sep 2022 | $21.29 M(-86.1%) | $2500.00(-100.0%) | $21.29 M(-9.4%) |
| Jun 2022 | - | $6.91 M(-41.6%) | $23.51 M(-77.8%) |
| Mar 2022 | - | $11.84 M(+366.0%) | $105.82 M(-18.5%) |
| Dec 2021 | - | $2.54 M(+14.3%) | $129.80 M(-15.3%) |
| Sep 2021 | $153.24 M(+440.5%) | $2.22 M(-97.5%) | $153.24 M(-3.6%) |
| Jun 2021 | - | $89.22 M(+149.1%) | $158.90 M(+112.5%) |
| Mar 2021 | - | $35.82 M(+37.9%) | $74.78 M(+72.6%) |
| Dec 2020 | - | $25.98 M(+229.5%) | $43.33 M(+52.8%) |
| Sep 2020 | $28.35 M(+59.4%) | $7.88 M(+54.6%) | $28.35 M(+18.4%) |
| Jun 2020 | - | $5.10 M(+16.8%) | $23.94 M(-14.9%) |
| Mar 2020 | - | $4.37 M(-60.3%) | $28.13 M(+4.8%) |
| Dec 2019 | - | $11.00 M(+216.9%) | $26.84 M(+50.9%) |
| Sep 2019 | $17.78 M(+120.3%) | $3.47 M(-62.7%) | $17.78 M(+15.0%) |
| Jun 2019 | - | $9.29 M(+202.3%) | $15.47 M(+83.4%) |
| Mar 2019 | - | $3.07 M(+58.1%) | $8.43 M(+45.7%) |
| Dec 2018 | - | $1.94 M(+68.2%) | $5.79 M(-28.3%) |
| Sep 2018 | $8.07 M(-70.4%) | $1.16 M(-48.8%) | $8.07 M(-31.3%) |
| Jun 2018 | - | $2.26 M(+426.7%) | $11.76 M(-15.5%) |
| Mar 2018 | - | $428.90 K(-89.9%) | $13.91 M(-15.0%) |
| Dec 2017 | - | $4.23 M(-12.6%) | $16.37 M(-40.0%) |
| Sep 2017 | $27.27 M(+770.5%) | $4.84 M(+9.6%) | $27.27 M(+14.8%) |
| Jun 2017 | - | $4.42 M(+52.9%) | $23.75 M(+22.8%) |
| Mar 2017 | - | $2.89 M(-80.9%) | $19.34 M(+17.6%) |
| Dec 2016 | - | $15.13 M(+1043.5%) | $16.45 M(+425.2%) |
| Sep 2016 | $3.13 M(-74.4%) | $1.32 M(>+9900.0%) | $3.13 M(-70.4%) |
| Jun 2016 | - | $0.00(0.0%) | $10.57 M(-22.6%) |
| Mar 2016 | - | $0.00(-100.0%) | $13.65 M(0.0%) |
| Dec 2015 | - | $1.81 M(-79.3%) | $13.65 M(+11.4%) |
| Sep 2015 | $12.26 M(+27.9%) | $8.76 M(+184.4%) | $12.26 M(+250.9%) |
| Jun 2015 | - | $3.08 M(>+9900.0%) | $3.49 M(+875.7%) |
| Mar 2015 | - | $0.00(-100.0%) | $358.00 K(-96.3%) |
| Dec 2014 | - | $411.90 K(>+9900.0%) | $9.80 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | $9.58 M(+762.0%) | $0.00(-100.0%) | $9.58 M(-8.0%) |
| Jun 2014 | - | -$53.90 K(-100.6%) | $10.41 M(-0.8%) |
| Mar 2014 | - | $9.45 M(+4918.7%) | $10.49 M(+854.6%) |
| Dec 2013 | - | $188.20 K(-77.3%) | $1.10 M(-1.1%) |
| Sep 2013 | $1.11 M(-29.2%) | $827.90 K(+2386.2%) | $1.11 M(+110.3%) |
| Jun 2013 | - | $33.30 K(-33.4%) | $528.40 K(-7.8%) |
| Mar 2013 | - | $50.00 K(-75.0%) | $573.40 K(-29.0%) |
| Dec 2012 | - | $200.00 K(-18.4%) | $807.20 K(-48.6%) |
| Sep 2012 | $1.57 M(-57.2%) | $245.10 K(+213.0%) | $1.57 M(+35.4%) |
| Jun 2012 | - | $78.30 K(-72.4%) | $1.16 M(-66.9%) |
| Mar 2012 | - | $283.80 K(-70.5%) | $3.51 M(+3.4%) |
| Dec 2011 | - | $962.50 K(-681.9%) | $3.39 M(-7.6%) |
| Sep 2011 | $3.67 M(-18.6%) | -$165.40 K(-106.8%) | $3.67 M(-14.8%) |
| Jun 2011 | - | $2.42 M(+1336.6%) | $4.31 M(+0.3%) |
| Mar 2011 | - | $168.80 K(-86.4%) | $4.30 M(-19.0%) |
| Dec 2010 | - | $1.24 M(+162.8%) | $5.30 M(+17.6%) |
| Sep 2010 | $4.51 M(+43.6%) | $473.10 K(-80.4%) | $4.51 M(-2.3%) |
| Jun 2010 | - | $2.41 M(+105.4%) | $4.62 M(+14.0%) |
| Mar 2010 | - | $1.17 M(+161.0%) | $4.05 M(+21.7%) |
| Dec 2009 | - | $450.00 K(-22.5%) | $3.33 M(+6.0%) |
| Sep 2009 | $3.14 M(+26.6%) | $581.00 K(-68.5%) | $3.14 M(-2.5%) |
| Jun 2009 | - | $1.85 M(+308.5%) | $3.22 M(+61.3%) |
| Mar 2009 | - | $451.70 K(+72.0%) | $2.00 M(-1.2%) |
| Dec 2008 | - | $262.60 K(-60.2%) | $2.02 M(-18.6%) |
| Sep 2008 | $2.48 M(+692.8%) | $660.40 K(+6.3%) | $2.48 M(+31.9%) |
| Jun 2008 | - | $621.10 K(+30.8%) | $1.88 M(+29.9%) |
| Mar 2008 | - | $475.00 K(-34.5%) | $1.45 M(+39.5%) |
| Dec 2007 | - | $725.00 K(+1108.3%) | $1.04 M(+231.6%) |
| Sep 2007 | $313.00 K(+616.2%) | $60.00 K(-68.1%) | $313.00 K(+9.2%) |
| Jun 2007 | - | $188.00 K(+189.2%) | $286.70 K(+214.0%) |
| Mar 2007 | - | $65.00 K(>+9900.0%) | $91.30 K(+108.9%) |
| Dec 2006 | - | $0.00(-100.0%) | $43.70 K(0.0%) |
| Sep 2006 | $43.70 K(+28.9%) | $33.70 K(-555.4%) | $43.70 K(+131.2%) |
| Jun 2006 | - | -$7400.00(-142.5%) | $18.90 K(-28.1%) |
| Mar 2006 | - | $17.40 K(>+9900.0%) | $26.30 K(-22.4%) |
| Dec 2005 | - | $0.00(-100.0%) | $33.90 K(0.0%) |
| Sep 2005 | $33.90 K(-15.3%) | $8900.00(>+9900.0%) | $33.90 K(+35.6%) |
| Jun 2005 | - | $0.00(-100.0%) | $25.00 K(0.0%) |
| Mar 2005 | - | $25.00 K(>+9900.0%) | $25.00 K(>+9900.0%) |
| Dec 2004 | - | $0.00 | $0.00 |
| Sep 2004 | $40.00 K | - | - |
FAQ
- What is Anavex Life Sciences annual cash flow from financing activities?
- What is the all time high annual CFF for Anavex Life Sciences?
- What is Anavex Life Sciences annual CFF year-on-year change?
- What is Anavex Life Sciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly CFF year-on-year change?
- What is Anavex Life Sciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Anavex Life Sciences?
- What is Anavex Life Sciences TTM CFF year-on-year change?
What is Anavex Life Sciences annual cash flow from financing activities?
The current annual CFF of AVXL is $11.97 M
What is the all time high annual CFF for Anavex Life Sciences?
Anavex Life Sciences all-time high annual cash flow from financing activities is $153.24 M
What is Anavex Life Sciences annual CFF year-on-year change?
Over the past year, AVXL annual cash flow from financing activities has changed by -$17.68 M (-59.61%)
What is Anavex Life Sciences quarterly cash flow from financing activities?
The current quarterly CFF of AVXL is $89.00 K
What is the all time high quarterly CFF for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly cash flow from financing activities is $89.22 M
What is Anavex Life Sciences quarterly CFF year-on-year change?
Over the past year, AVXL quarterly cash flow from financing activities has changed by -$4.46 M (-98.04%)
What is Anavex Life Sciences TTM cash flow from financing activities?
The current TTM CFF of AVXL is $11.97 M
What is the all time high TTM CFF for Anavex Life Sciences?
Anavex Life Sciences all-time high TTM cash flow from financing activities is $158.90 M
What is Anavex Life Sciences TTM CFF year-on-year change?
Over the past year, AVXL TTM cash flow from financing activities has changed by -$1.97 M (-14.11%)